Keratin 17 is a sensitive and specific biomarker of urothelial neoplasia.


Journal

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605

Informations de publication

Date de publication:
05 2019
Historique:
received: 18 06 2018
accepted: 26 10 2018
revised: 18 10 2018
pubmed: 18 11 2018
medline: 28 4 2020
entrez: 17 11 2018
Statut: ppublish

Résumé

There is a clinical need to identify novel biomarkers to improve diagnostic accuracy for the detection of urothelial tumors. The current study aimed to evaluate keratin 17 (K17), an oncoprotein that drives cell cycle progression in cancers of multiple anatomic sites, as a diagnostic biomarker of urothelial neoplasia in bladder biopsies and in urine cytology specimens. We evaluated K17 expression by immunohistochemistry in formalin-fixed, paraffin embedded tissue specimens of non-papillary invasive urothelial carcinoma (UC) (classical histological cases), high grade papillary UC (PUC-LG), low grade papillary UC (PUC-HG), papillary urothelial neoplasia of low malignant potential (PUNLMP), and normal bladder mucosa. A threshold was established to dichotomize K17 status in tissue specimens as positive vs. negative, based on the proportion of cells that showed strong staining. In addition, K17 immunocytochemistry was performed on urine cytology slides, scoring positive test results based on the detection of K17 in any urothelial cells. Mann-Whitney and receiver operating characteristic analyses were used to compare K17 expression between histologic diagnostic categories. The median proportion of K17 positive tumor cells was 70% (range 20-90%) in PUNLMP, 30% (range 5-100%) in PUC-LG, 20% (range 1-100%), in PUC-HG, 35% (range 5-100%) in UC but staining was rarely detected (range 0-10%) in normal urothelial mucosa. Defining cases in which K17 was detected in ≥10% of cells were considered positive, the sensitivity of K17 in biopsies was 89% (95% CI: 80-96%) and the specificity was 88% (95% CI: 70-95%) to distinguish malignant lesions (PUC-LG, PUC-HG, and UC) from normal urothelial mucosa. Furthermore, K17 immunocytochemistry had a sensitivity of 100% and a specificity of 96% for urothelial carcinoma in 112 selected urine specimens. Thus, K17 is a sensitive and specific biomarker of urothelial neoplasia in tissue specimens and should be further explored as a novel biomarker for the cytologic diagnosis of urine specimens.

Identifiants

pubmed: 30443013
doi: 10.1038/s41379-018-0177-5
pii: S0893-3952(22)01082-1
doi:

Substances chimiques

Biomarkers, Tumor 0
KRT17 protein, human 0
Keratin-17 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

717-724

Auteurs

Sruthi Babu (S)

Department of Pathology, Stony Brook Medicine, Stony Brook, NY, USA.
Program of Public Health and Department of Preventative Medicine, Stony Brook Medicine, Stony Brook, NY, USA.

Daniel C Mockler (DC)

Department of Pathology, Stony Brook Medicine, Stony Brook, NY, USA.

Lucia Roa-Peña (L)

Department of Pathology, Stony Brook Medicine, Stony Brook, NY, USA.

Agnieszka Szygalowicz (A)

Department of Pathology, Stony Brook Medicine, Stony Brook, NY, USA.

Nam W Kim (NW)

KDx Diagnostics Inc, Campbell, CA, USA.

Sholeh Jahanfard (S)

KDx Diagnostics Inc, Campbell, CA, USA.

Shahram S Gholami (SS)

KDx Diagnostics Inc, Campbell, CA, USA.

Richard Moffitt (R)

Department of Pathology, Stony Brook Medicine, Stony Brook, NY, USA.
Department of Biomedical Informatics, Stony Brook Medicine, Stony Brook, NY, USA.

John P Fitzgerald (JP)

Department of Urology, Stony Brook Medicine, Stony Brook, NY, USA.

Luisa F Escobar-Hoyos (LF)

Department of Pathology, Stony Brook Medicine, Stony Brook, NY, USA. luisa.escobarhoyos@stonybrookmedicine.edu.
David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York, 10065, USA. luisa.escobarhoyos@stonybrookmedicine.edu.
Department of Biology, Genetic Toxicology and Cytogenetics Research Group, School of Natural Sciences and Education, Universidad Del Cauca, Popayán, Colombia. luisa.escobarhoyos@stonybrookmedicine.edu.

Kenneth R Shroyer (KR)

Department of Pathology, Stony Brook Medicine, Stony Brook, NY, USA. Kenneth.Shroyer@stonybrookmedicine.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH